- Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.
Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.
Nature communications (2017-09-06)
Nai-Jia Huang, Novalia Pishesha, Jean Mukherjee, Sicai Zhang, Rhogerry Deshycka, Valentino Sudaryo, Min Dong, Charles B Shoemaker, Harvey F Lodish
PMID28871080
RESUMEN
A short half-life in the circulation limits the application of therapeutics such as single-domain antibodies (VHHs). We utilize red blood cells to prolong the circulatory half-life of VHHs. Here we present VHHs against botulinum neurotoxin A (BoNT/A) on the surface of red blood cells by expressing chimeric proteins of VHHs with Glycophorin A or Kell. Mice whose red blood cells carry the chimeric proteins exhibit resistance to 10,000 times the lethal dose (LD